Iron in multiple sclerosis: Roles in neurodegeneration and repair

Nature Reviews Neurology

Volumn 10, Issue 8, 2014, Pages 459-468

  Stephenson, Erin ^a   Nathoo, Nabeela ^a   Mahjoub, Yasamin ^a   Dunn, Jeff F ^a   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; ERYTHROPOIETIN; FERRIC ION; FERRITIN; FERROUS ION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IRON; IRON CHELATING AGENT; IRON REGULATORY FACTOR; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANTIOXIDANT ACTIVITY; CELL FUNCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; IRON BALANCE; IRON CHELATION; IRON DEFICIENCY; IRON DEPLETION; IRON OVERLOAD; IRON STORAGE; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVE REGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; REMYELINIZATION; REVIEW;

ADULT; BRAIN; BRAIN CHEMISTRY; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA;

EID: 84906101044     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.118     Document Type: Review

References (121)

1. Ropele, S. et al. MRI assessment of iron deposition in multiple sclerosis. J. Magn. Reson. Imaging 34, 13-21 (2011).
2. Chavhan, G. B., Babyn, P. S., Thomas, B., Shroff, M. M. & Haacke, E. M. Principles, techniques, and applications of T2*-based MR imaging and its special applications. Radiographics 29, 1433-1449 (2009).
3. Haider, L. et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry http://dx.doi.com/10.1136/jnnp-2014-307712.
4. Walsh, A. et al. Multiple sclerosis: validation of MR imaging for quantification and detection of iron. Radiology 267, 531-542 (2013).
5. Zheng, W., Nichol, H., Liu, S., Cheng, Y.-C. & Haacke, E. M. Measuring iron in the brain using quantitative susceptibility mapping and X-ray fluorescence imaging. Neuroimage 78, 68-74 (2013).
6. Yao, B. et al. Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 262, 206-215 (2012).
7. Bagnato, F. et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 134, 3602-3615 (2011).
8. Reichard, P. & Ehrenberg, A. Ribonucleotide reductase-a radical enzyme. Science 221, 514-519 (1983).
9. Outten, F. W. & Theil, E. C. Iron-based redox switches in biology. Antioxid. Redox Signal. 11, 1029-1046 (2009).
10. Núñez, M. T. et al. Iron toxicity in neurodegeneration. Biometals 25, 761-776 (2012).
11. Koskenkorva-Frank, T., Weiss, G., Koppenol, W. & Burckhardt, S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med. 65, 1174-1194 (2013).
12. Fridovich, I. Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann. N. Y. Acad. Sci. 893, 13-18 (1999).
13. Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M. & Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160, 1-40 (2006).
14. Esposito, B. P. et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670-2677 (2003).
15. Li, H., Swiercz, R. & Englander, E. W. Elevated metals compromise repair of oxidative DNA damage via the base excision repair pathway: implications of pathologic iron overload in the brain on integrity of neuronal DNA. J. Neurochem. 110, 1774-1783 (2009).
16. Yakes, F. & Van Houten, B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl Acad. Sci. USA 94, 514-519 (1997).
17. Shen, G. X. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can. J. Physiol. Pharmacol. 88, 241-248 (2010).
18. Mahad, D., Ziabreva, I., Lassmann, H. & Turnbull, D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722-1735 (2008).
19. Trapp, B. D. & Stys, P. K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8, 280-291 (2009).
20. Eaton, J. W. & Qian, M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 32, 833-840 (2002).
21. Kress, G. J., Dineley, K. E. & Reynolds, I. J. The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. J. Neurosci. 22, 5848-5855 (2002).
22. Iwata-Ichikawa, E., Kondo, Y., Miyazaki, I., Asanuma, M. & Ogawa, N. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J. Neurochem. 72, 2334-2344 (1999).
23. Makar, T. et al. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem. 62, 45-53 (1994).
24. Thorburne, S. K. & Juurlink, B. H. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J. Neurochem. 67, 1014-1022 (1996).
25. Benkovic, S. A. & Connor, J. R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 338, 97-113 (1993).
26. Connor, J. R. & Menzies, S. L. Relationship of iron to oligodendrocytes and myelination. Glia 17, 83-93 (1996).
27. Connor, J. R., Pavlick, G., Karli, D., Menzies, S. L. & Palmer, C. A histochemical study of iron-positive cells in the developing rat brain. J. Comp. Neurol. 355, 111-123 (1995).
28. Juurlink, B. H. Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. Neurosci. Biobehav. Rev. 21, 151-166 (1997).
29. Matute, C., Sánchez-Gómez, M. V., Martínez- Millán, L. & Miledi, R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc. Natl Acad. Sci. USA 94, 8830-8835 (1997).
30. Yu, J. et al. Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons. Brain Res. 1257, 102-107 (2009).
31. McGahan, M. C. et al. Iron alters glutamate secretion by regulating cytosolic aconitase activity. Am. J. Physiol. Cell Physiol. 288, C1117-C1124 (2005).
32. Káradóttir, R., Cavelier, P., Bergersen, L. H. & Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438, 1162-1166 (2005).
33. Cui, Q.-L. et al. Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis. Am. J. Pathol. 183, 516-525 (2013).
34. Hametner, S. et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 74, 848-861 (2013).
35. Durafourt, B. A. et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60, 717-727 (2012).
36. Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164, 6166-6173 (2000).
37. Sindrilaru, A. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121, 985-997 (2011).
38. Mehta, V. et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS ONE 8, e57573 (2013).
39. Friese, M. A., Schattling, B. & Fugger, L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat. Rev. Neurol. 10, 225-238 (2014).
40. Bamm, V. V. & Harauz, G. Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders? Cell. Mol. Life Sci. 71, 1789-1798 (2014).
41. Adams, C. W. Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 51, 260-265 (1988).
42. Balla, J. et al. Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol. Nutr. Food Res. 49, 1030-1043 (2005).
43. Nathoo, N. et al. Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination. Mult. Scler. 19, 721-731 (2013).
44. Williams, R. et al. Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neurosci. 12, 59 (2011).
45. Cornelia, S. et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol. http://dx.doi.org/10.1007/s00401-014-1263-5.
46. Cammer, W. in Oligodendroglia (ed. Norton, W. T.) 199-232 (Springer, 1984). [Series Ed. Agranoff, B. W. & Suzuki, K. Advances in Neurochemistry Vol. 5].
47. Chang, A. et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann. Neurol. 72, 918-926 (2012).
48. Gille, G. & Reichmann, H. Iron-dependent functions of mitochondria-relation to neurodegeneration. J. Neural Transm. 118, 349-359 (2011).
49. Pleasure, D. & Kim, S. U. Enzyme markers for myelination of mouse cerebellum in vivo and in tissue culture. Brain Res. 104, 193-196 (1976).
50. Saher, G., et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8, 468-475 (2005).
51. Lange, S. J. & Que, L. Jr. Oxygen activating nonheme iron enzymes. Curr. Opin. Chem. Biol. 2, 159-172 (1998).
52. Todorich, B., Pasquini, J. M., Garcia, C. I., Paez, P. M. & Connor, J. R. Oligodendrocytes and myelination: the role of iron. Glia 57, 467-478 (2009).
53. Schonberg, D. L. & McTigue, D. M. Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation. Exp. Neurol. 218, 64-74 (2009).
54. Schulz, K., Kroner, A. & David, S. Iron efflux from astrocytes plays a role in remyelination. J. Neurosci. 32, 4841-4847 (2012).
55. Morath, D. J. & Mayer-Proschel, M. Iron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes. Dev. Biol. 237, 232-243 (2001).
56. Beard, J. L., Wiesinger, J. A. & Connor, J. R. Pre- and postweaning iron deficiency alters myelination in Sprague-Dawley rats. Dev. Neurosci. 25, 308-315 (2003).
57. Lieblein-Boff, J. C. et al. Neonatal E. coli infection causes neuro-behavioral deficits associated with hypomyelination and neuronal sequestration of iron. J. Neurosci. 33, 16334-16345 (2013).
58. Badaracco, M. E., Siri, M. V. & Pasquini, J. M. Oligodendrogenesis: the role of iron. Biofactors 36, 98-102 (2010).
59. Arnett, H. A. et al. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116-1122 (2001).
60. Mason, J. L., Suzuki, K., Chaplin, D. D. & Matsushima, G. K. Interleukin-1β promotes repair of the CNS. J. Neurosci. 21, 7046-7052 (2001).
61. Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J. & Matsushima, G. K. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J. Neurosci. 20, 5703-5708 (2000).
62. Zeger, M. et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55, 400-411 (2007).
63. Zhang, X., Surguladze, N., Slagle-Webb, B., Cozzi, A. & Connor, J. R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54, 795-804 (2006).
64. Schonberg, D. L. et al. Ferritin stimulates oligodendrocyte genesis in the adult spinal cord and can be transferred from macrophages to NG2 cells in vivo. J. Neurosci. 32, 5374-5384 (2012).
65. Cairo, G., Recalcati, S., Mantovani, A. & Locati, M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 32, 241-247 (2011).
66. Corna, G. et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95, 1814-1822 (2010).
67. Orino, K., et al. Ferritin and the response to oxidative stress. Biochem. J. 357, 241-247 (2001).
68. Connor, J. R. & Benkovic, S. A. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann. Neurol. 32 (Suppl.), S51-S61 (1992).
69. Benkovic, S. A. & Connor, J. R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 338, 97-113 (1993).
70. Brissot, P., Ropert, M., Le Lan, C. & Loréal, O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochimic. Biophys. Acta 1820, 403-410 (2012).
71. Petrat, F., de Groot, H. & Rauen, U. Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem. J. 356, 61-69 (2001).
72. Moos, T. Brain iron homeostasis. Dan. Med. Bull. 49, 279-301 (2002).
73. Rouault, T. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 551-564 (2013).
74. Schulz, K., Vulpe, C. D., Harris, L. Z. & David, S. Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J. Neurosci. 31, 13301-13311 (2011).
75. Rouault, T. A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2, 406-414 (2006).
76. Peyssonnaux, C., Nizet, V. & Johnson, R. S. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7, 28-32 (2008).
77. Rouault, T. A. & Cooperman, S. Brain iron metabolism. Semin. Pediatr. Neurol. 13, 142-148 (2006).
78. Anderson, C. P., Shen, M., Eisenstein, R. S. & Leibold, E. A. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 1823, 1468-1483 (2012).
79. Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S. & Yong, V. W. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat. Rev. Neurosci. 14, 722-729 (2013).
80. Morawski, M. et al. Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology. Brain Pathol. 22, 547-561 (2012).
81. Sayed, R., Mubarak, W., Ohtsuka, A., Taguchi, T. & Murakami, T. Histochemical study of perineuronal nets in the retrosplenial cortex of adult rats. Ann. Anat. 184, 333-339 (2002).
82. Morawski, M., Brückner, M., Riederer, P., Brückner, G. & Arendt, T. Perineuronal nets potentially protect against oxidative stress. Exp. Neurol. 188, 309-315 (2004).
83. Bonneh-Barkay, D. & Wiley, C. A. Brain extracellular matrix in neurodegeneration. Brain Pathol. 19, 573-585 (2009).
84. Fiedler, A. et al. Intracellular iron concentration of neurons with and without perineuronal nets. Nucl. Instrum. Methods Phys. Res. B 260, 153-158 (2007).
85. Suttkus, A., Rohn, S., Jäger, C., Arendt, T. & Morawski, M. Neuroprotection against iron-induced cell death by perineuronal nets-an in vivo analysis of oxidative stress. Am. J. Neurodegener. Dis. 1, 122-129 (2012).
86. Suttkus, A. et al. Aggrecan, link protein and tenascin-R are essential components of the perineuronal net to protect neurons against iron-induced oxidative stress. Cell Death Dis. 5, e1119 (2014).
87. Sobel, R. A. & Ahmed, A. S. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J. Neuropathol. Exp. Neurol. 60, 1198-1207 (2001).
88. Bekku, Y. et al. Bral1: its role in diffusion barrier formation and conduction velocity in the CNS. J. Neurosci. 30, 3113-3123 (2010).
89. Lau, L. W. et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann. Neurol. 72, 419-432 (2012).
90. Chun, S. J., Rasband, M. N., Sidman, R. L., Habib, A. A. & Vartanian, T. Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J. Cell Biol. 163, 397-408 (2003).
91. Colognato, H., ffrench-Constant, C. & Feltri, M. L. Human diseases reveal novel roles for neural laminins. Trends Neurosci. 28, 480-486 (2005).
92. Nakanishi, K., Ito, M., Sato, Y. & Oohira, A. A highly-sulfated chondroitin sulfate, CS-E, adsorbs specifically to neurons with nuclear condensation. Neurosci. Res. 74, 223-229 (2012).
93. Grant, S. M., Wiesinger, J. A., Beard, J. L. & Cantorna, M. T. Iron-deficient mice fail to develop autoimmune encephalomyelitis. J. Nutr. 133, 2635-2638 (2003).
94. Brock, J. H. & Stevenson, J. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator. Immunol. Lett. 15, 23-25 (1987).
95. Kuvibidila, S., Dardenne, M., Savino, W. & Lepault, F. Influence of iron-deficiency anemia on selected thymus functions in mice: thymulin biological activity, T-cell subsets, and thymocyte proliferation. Am. J. Clin. Nutr. 51, 228-232 (1990).
96. Semenza, G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88, 1474-1480 (2000).
97. Peyssonnaux, C. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 117, 1926-1932 (2007).
98. Lynch, S. G., Peters, K. & LeVine, S. M. Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult. Scler. 2, 157-160 (1996).
99. Lynch, S. G., Fonseca, T. & LeVine, S. M. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell. Mol. Biol. (Noisy-le-grand) 46, 865-869 (2000).
100. Norstrand, I. F. & Craelius, W. A trial of deferoxamine (Desferal) in the treatment of multiple sclerosis. A pilot study. Clin. Trials J. 26, 365-369 (1989).
101. Weigel, K. J., Lynch, S. G. & LeVine, S. M. Iron chelation and multiple sclerosis. ASN Neuro. 6, e00136 (2014).
102. Créange, A., Lefaucheur, J. P., Balleyguier, M. O. & Galactéros, F. Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: a pilot, open-label study with neurophysiological measurements. Neurophysiol. Clin. 43, 303-312 (2013).
103. Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8, 647-656 (2012).
104. Mirshafiey, A. & Mohsenzadegan, M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 31, 13-29 (2009).
105. Schwarz, S. & Leweling, H. Multiple sclerosis and nutrition. Mult. Scler. 11, 24-32 (2005).
106. Zhang, S. M. et al. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 57, 75-80 (2001).
107. Halliwell, B. & Gutteridge, J. The importance of free radicals and catalytic metal ions in human diseases. Mol. Aspects Med. 8, 89-193 (1985).
108. Kell, D. B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2 (2009).
109. Youdim, M. B., Ben-Shachar, D. & Riederer, P. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8, 1-12 (1993).
110. Berg, D., Becker, G., Riederer, P. & Riess, O. Iron in neurodegenerative disorders. Neurotox. Res. 4, 637-653 (2002).
111. Balla, J. et al. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol. Dial. Transplant. 18 (Suppl. 5), v8-v12 (2003).
112. Hammond, K. E. et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann. Neurol. 64, 707-713 (2008).
113. Walsh, A. J. et al. Longitudinal MR imaging of iron in multiple sclerosis: an imaging marker of disease. Radiology 270, 186-196 (2014).
114. Khalil, M. et al. Determinants of brain iron in multiple sclerosis: a quantitative 3 T MRI study. Neurology 77, 1691-1697 (2011).
115. Al-Radaideh, A. et al. Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in clinically isolated syndrome. Mult. Scler. 19, 896-903 (2013).
116. Lebel, R. M., Eissa, A., Seres, P., Blevins, G. & Wilman, A. H. Quantitative high-field imaging of sub-cortical gray matter in multiple sclerosis. Mult. Scler. 18, 433-441 (2012).
117. 2* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult. Scler. 15, 1048-1054 (2009).
118. Zivadinov, R. et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 59, 331-339 (2012).
119. Neema, M. et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J. Neuroimaging 19, 3-8 (2009).
120. Paling, D. et al. Reduced R2' in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content. J. Neurol. Neurosurg. Psychiatry 83, 785-792 (2012).
121. Forge, J. K., Pedchenko, T. V. & LeVine, S. M. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci. 63, 2271-2284 (1998).